The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

BAKU, Azerbaijan, August 7. Cooperation in the development of the Baku-Tbilisi-Kars (BTK) railway line was discussed during a ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Discover BeOne Medicines' robust Q2 2025 performance, with 42% revenue growth, market leadership in oncology, and raised 2025 guidance.

Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, everyone. Welcome to BeOne Q2 2025 Earnings Call Webcast. [Operator Instructions] At this time, I would like to turn the call over ...

Eli Lilly has shared positive top-line results from a head-to-head study of its non-covalent Bruton’s tyrosine kinase (BTK) ...

A key meeting took place in Baku between Rovshan Rustamov, Chairman of Azerbaijan Railways CJSC (ADY), a subsidiary of AZCON ...

BeOne Medicines Ltd (SHSE:688235) reports a 42% revenue surge and strategic advancements, while navigating market pressures and regulatory complexities.